alexa Companion Diagnostics: Technical, Regulatory And Reimbursement Challenges For The 21st Century
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Richard A. Montagna
ScientificTracks Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.008
Abstract
Companion diagnostics provides a powerful means to use specific biomarkers to stratify patients into responders and non- responders, thus facilitating the administration of the proper drug at the proper dose to the proper patient subpopulation. Moreover, such stratification reduces healthcare costs by avoiding the administration of expensive drugs to non-responders while at the same time decreasing potential adverse drug reactions and their associated hospitalization costs. The development and FDA clearance of companion diagnostics must now adhere to new guidelines established by the Agency to assure co-development and contemporaneous regulatory submissions of both a drug and its companion diagnostic. The costs and risks associated with the potential failure of a drug trial during any of its clinical trial phases complicates the decision making process regarding the initiation of development efforts for the associated companion diagnostic. While a failed drug trial will render its associated companion diagnostic of no value, a failed diagnostic trial could potentially sideline and prevent an innovative new therapeutic from reaching the intended patient population. Coupled with these significant risks are the new challenges associated with the rapidly changing reimbursement landscape in the U.S. Not only have the former molecular diagnostic ?stacking? CPT codes been replaced by corresponding ?bundled? codes, but the reimbursement rates have declined on average by 25-35 percent and in some cases even more. Many of these challenges can be overcome by the availability of fully automated molecular diagnostic platforms that can be rapidly configured to detect and quantitate the biomarkers of interest.
Biography
Richard A. Montagna holds a Ph.D. in Molecular Biology and is Senior Vice President for Scientific Affairs at Rheonix, Inc. where he oversees regulatory and reimbursement issues. He is also an Adjunct Professor at Cornell University (Dept. of Biological& Environmental Engineering), has been awarded over $5.5 Million of grant funding as Principal Investigator, published 40 peer-reviewed scientific papers, and led the commercialization of over 40 biotech products, including FDA approved diagnostics. In 1988 he testified before President Reagan?s AIDS commission regarding the prevalence of HTLV-1 antibodies in the US blood supply, urging the commission to mandate nationwide blood screening, which was implemented within one year.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords